FDA Blocks Vaccine Safety Study Publications

Officials at the Food and Drug Administration have recently prevented the publication of studies that affirmed the safety of widely utilized Covid-19 and shingles vaccines. These studies, which involved analyzing millions of patient records and cost millions in public funds, indicated that severe side effects were infrequent.

In October, scientists were directed to retract two Covid-19 vaccine studies that had been accepted by medical journals. Subsequently, in February, top FDA officials declined to approve abstracts for studies on the shingles vaccine, Shingrix, for submission to a drug safety conference.

Critics argue that these actions constitute censorship and sabotage, potentially undermining public trust. The FDA stated the studies were withdrawn because their conclusions were not adequately supported by the data, aiming to preserve the integrity of the agency's scientific processes. However, external experts who reviewed the studies found them to be generally well-executed and useful.

These decisions follow other instances where information supporting vaccine safety has been limited, including requests to remove content casting doubt on vaccines and blocking papers on vaccine effectiveness. The full implications of these withheld studies on public understanding and trust in vaccines remain a significant concern.